| |
|
| P-Mark Project : Publications |
|
Is Prostate-Specific Antigen Velocity Selective for Clinically Significant Prostate Cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).
Wolters T, Roobol MJ, Bangma CH, Schröder FH.
Eur Urol 2009 [Epub ahead of print].
Download
URL : Abstract
|
|
Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer.
Jhavar S, Brewer D, Edwards S, Kote-Jarai Z, Attard G, Clark J, Flohr P, Christmas T, Thompson A, Parker M, Shepherd C, Stenman UH, Marchbank T, Playford RJ, Woodhouse C, Ogden C, Fisher C, Kovacs G, Corbishley C, Jameson C, Norman A, De-Bono J, Bjartell
BJU Int. 2009 [Epub ahead of print].
Download
URL : Abstract
|
|
Evaluation of molecular forms of PSA and human kallikrein 2 in predicting biochemical failure following radical prostatectomy.
Wenske S, Korets R, Cronin AM, Vickers AJ, Fleisher M, Scher HI, Pettersson K, Guillonneau B, Scardino PT, Eastham JA, Lilja H.
Int J Cancer 2009;124:659-663.
Download
URL : Abstract
|
|
Digital Rectal Examination and the Diagnosis of Prostate Cancer-a Study Based on 8 Years and Three Screenings within the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam.
Gosselaar C, Roobol MJ, van den Bergh RC, Wolters T, Schröder FH.
Eur Urol 2009 [Epub ahead of print].
Download
URL : Abstract
|
|
Outcomes of Men with Screen-Detected Prostate Cancer Eligible for Active Surveillance Who Were Managed Expectantly.
van den Bergh RC, Roemeling S, Roobol MJ, Aus G, Hugosson J, Rannikko AS, Tammela TL, Bangma CH, Schröder FH.
Eur Urol 2009;55:1-8.
Download
URL : Abstract
|
|
Increase in percent free prostate-specific antigen in men with chronic kidney disease
Bruun L, Savage C, Cronin AM, Hugosson J, Lilja H, Christensson A.
Nephrol Dial Transplant. 2008; (Epub ahead of print).
Download
URL : Abstract
|
|
A graphical device to represent the outcomes of a logistic regression analysis.
Kranse R, Roobol MJ, Schröder FH.
Prostate 2008;68:1674-80.
Download
URL : Abstract
|
|
The Prostate Cancer Prevention Trial and European Randomized Study of Screening for Prostate Cancer risk calculators indicating a positive prostate biopsy: a comparison.
van den Bergh RC, Roobol MJ, Wolters T, van Leeuwen PJ, Schröder FH.
BJU Int 2008;102:1068-73.
Download
URL : Abstract
|
|
Clinical Utility of the PCA3 Urine Assay in European Men Scheduled for Repeat Biopsy.
Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Abbou CC, Remzi M, Tinzl M, Feyerabend S, Stillebroer AB, van Gils MP, Schalken JA.
Eur Urol 2008;54:1081-8.
Download
URL : Abstract
|
|
Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results.
van Gils MP, Hessels D, Hulsbergen-van de Kaa CA, Witjes JA, Jansen CF, Mulders PF, Rittenhouse HG, Schalken JA.
Prostate 2008;68:1215-22.
Download
URL : Abstract
|
|
A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden.
Vickers AJ, Cronin AM, Aus G, Pihl CG, Becker C, Pettersson K, Scardino PT, Hugosson J, Lilja H.
BMC Med 2008;6:19.
Download
URL : Full text (PDF)
|
|
FGF-8b is involved in bone metastasis of prostate cancer bone.
Valta MP, Tuomela J, Bjartell A, Valve E, Väänänen HK, Härkönen P.
Int J Cancer 2008;123:22-31.
Download
URL : Abstract
|
|
Testing New PSA Subforms to Enhance the Accuracy of Predicting Cancer Risk and Disease Outcome in Prostate Cancer.
Lilja H.
Clin Chem 2008;54:1248-1249.
Download
URL : Extract
|
|
The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer.
Gosselaar C, Kranse R, Roobol MJ, Roemeling S, Schröder FH.
Prostate 2008;68:985-93.
Download
URL : Abstract
|
|
The role of SPINK1 in ETS rearrangement-negative prostate cancers.
Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, Perner S, Demichelis F, Helgeson BE, Laxman B, Morris DS, Cao Q, Cao X, Andrén O, Fall K, Johnson L, Wei JT, Shah RB, Al-Ahmadie H, Eastham JA, Eggener SE, Fine SW, Hotakainen K, Stenman UH, Tsodikov A,
Cancer Cell 2008;13:519-28.
Download
URL : Abstract
|
|
Launch of the PROCABIO project: tailored treatment of prostate cancer.
Schenk E, Bangma C.
European Urology Today 2008;20(3):13.
Download
|
|
Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels <3.0 ng/ml? A Comparison of Biopsy Results of PCPT and Outcome-Related Information from ERSPC.
Schröder FH, Bangma CH, Roobol MJ.
Eur Urol 2008;53:901-908.
Download
URL : Abstract
|
|
Association between polymorphisms in the prostate-specific antigen (PSA) promoter and release of PSA.
Sävblom C, Giwercman A, Malm J, Halldén C, Lundin K, Lilja H, Giwercman Y.
Int J Androl 2008; [Epub ahead of print].
Download
URL : Abstract
|
|
Early Detection of Prostate Cancer in 2007 Part 1: PSA and PSA Kinetics.
Schröder FH, Carter HB, Wolters T, van den Bergh RC, Gosselaar C, Bangma CH, Roobol MJ.
Eur Urol 2008;53:468-477.
Download
URL : Abstract
|
|
The value of an additional hypoechoic lesion-directed biopsy core for detecting prostate cancer.
Gosselaar C, Roobol MJ, Roemeling S, Wolters T, van Leenders GJLH, Schröder FH.
BJUI Int 2008;101;685-690.
Download
URL : Abstract
|
|
ENSAM: Europium Nanoparticles for Signal Enhancement of Antibody Microarrays on Nanoporous Silicon.
Järås K, Ahmad Tajudin A, Ressine A, Soukka T, Marko-Varga G, Bjartell A, Malm J, Laurell T, Lilja H.
J Proteome Res. 2008 Mar;7(3):1308-14.
Download
URL : Abstract
|
|
A software application for comparing large numbers of high resolution MALDI-FTICR MS spectra demonstrated by searching candidate biomarkers for glioma blood vessel formation.
Titulaer MK, Mustafa DA, Siccama I, Konijnenburg M, Burgers PC, Andeweg AC, Smitt PA, Kros JM, Luider TM.
BMC Bioinformatics. 2008 Mar 1;9:133.
Download
URL : Full text (PDF)
|
|
Long-Term Prediction of Prostate Cancer: Prostate-Specific Antigen (PSA) Velocity Is Predictive but Does Not Improve the Predictive Accuracy of a Single PSA Measurement 15 Years or More Before Cancer Diagnosis in a Large, Representative, Unscreened Popula
Ulmert D, Serio AM, Becker C, O’Brien MF, Eastham JA, Scardino PT, Björk T, Berglund G, Vickers AJ, Lilja H.
J Clin Oncol. 2008; 26: 835-841.
Download
URL : Abstract
|
|
Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study.
Ulmert D, Cronin AM, Björk T, O’Brien MF, Scardino PT, Eastham JA, Becker C, Berglund G, Vickers AJ, Lilja H.
BMC Medicine 2008; 6:6.
Download
URL : Full text (PDF)
|
|
Can non-malignant biopsy features identify men at increased risk of biopsy-detectable prostate cancer at re-screening after 4 years?
Wolters T, Roobol MJ, Schröder FH, van der Kwast TH, Roemeling S, van der Cruijsen-Koeter IW, Bangma CH, van Leenders GJ.
BJUI Int 2008;101:283-288.
Download
URL : Abstract
|
|
Quantitative real-time RT-PCR assay for PCA3.
Väänänen RM, Rissanen M, Kauko O, Junnila S, Väisänen V, Nurmi J, Alanen K, Nurmi M, Pettersson K.
Clin Biochem 2008;41:103-8.
Download
URL : Abstract
|
|
Overall Survival in the Intervention Arm of a Randomized Controlled Screening Trial for Prostate Cancer Compared with a Clinically Diagnosed Cohort.
Vis AN, Roemeling S, Reedijk AJM, Otto SJ, Schröder FH.
Eur Urol 2008;53:91-98.
Download
URL : Abstract
|
|
Increased expression of Tumor-Associated Trypsin Inhibitor, TATI, in Prostate Cancer and in Androgen-Independent 22Rv1 Cells.
Paju A, Hotakainen K, Cao Y, Laurila T, Gadaleanu V, Hemminki A, Stenman U-H, Bjartell A.
Eur Urol 2007;52:1670-1681.
Download
URL : Abstract
|
|
Editorial comment on: Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells.
Schalken J.
Eur Urol 2007;52:1679.
Download
URL : Full text
|
|
Nomogram use for the prediction of indolent prostate cancer: impact on screen-detected populations
Roemeling S, Roobol MJ, Kattan MW, van der Kwast TH, Steyerberg EW, Schröder FH.
Cancer 2007;110:2218-21.
Download
URL : Abstract
|
|
hK2 and Free PSA, a Prognostic Combination in Predicting Minimal Prostate Cancer in Screen-Detected Men within the PSA Range 4-10 ng/ml.
Raaijmakers R, De Vries SH, Blijenberg BG, Wildhagen MF, Postma R, Bangma CH, Darte C, Schröder FH.
Eur Urol 2007;52(5):1358-64.
Download
URL : Abstract
|
|
The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: Towards a biologically-based screening strategy.
Vickers AJ, Ulmert D, Serio AM, Björk T, Scardino PT, Eastham JA, Berglund G, Lilja H.
Int J Cancer. 2007;121:2212-2217.
Download
URL : Abstract
|
|
Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam.
Roobol MJ, Grenabo A, Schroder FH, Hugosson J.
J Natl Cancer Inst. 2007 ;99:1296-303.
Download
URL : Abstract
|
|
Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer.
Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB, Schalken JA.
Clin Cancer Res 2007;13:5103-8.
Download
URL : Abstract
|
|
Reverse-Phase versus Sandwich Antibody Micro array, Technical Comparison from a Clinical Perspective.
Järås K, Ressine A, Nilsson E, Malm J, Marko-Varga G, Lilja H, Laurell T.
Anal Chem 2007;79:5817-5825.
Download
URL : Abstract
|
|
Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy.
Bjartell AS, Al-Ahmadie H, Serio AM, Eastham JA, Eggener SE, Fine SW, Udby L, Gerald WL, Vickers AJ, Lilja H, Reuter VE, Scardino PT.
Clin Cancer Res 2007;13:4130-8
Download
URL : Abstract
|
|
Feasibility study of adjustment for contamination and non-compliance in a prostate cancer screening trial.
Roemeling S, Roobol MJ, Otto S, Habbema DF, Gosselaar C, Lous JJ, Cuzick J, Schröder FH.
Prostate 2007;67(10):1053-60.
Download
URL : Abstract
|
|
Molecular PCA3 diagnostics on prostatic fluid.
van Gils MP, Cornel EB, Hessels D, Peelen WP, Witjes JA, Mulders PF, Rittenhouse HG, Schalken JA.
Prostate. 2007;67:881-7.
Download
URL : Abstract
|
|
Overall Survival in the Intervention Arm of a Randomized Controlled Screening Trial for Prostate Cancer Compared with a clinically Diagnosed Cohort.
Vis AN, Roemeling S, Reedijk AM, Otto SJ, Schröder FH.
Eur Urol Epub 2007 Jun 12.
Download
URL : Abstract
|
|
Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome.
Roemeling S, Roobol MJ, De Vries SH, Wolters T, Gosselaar C, Van Leenders GJ, Schröder FH.
Eur Urol. 2007;51(5):1244-50; discussion 1251.
Download
URL : Abstract
|
|
Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy.
Steuber T, Vickers A, Haese A, Kattan MW, Eastham JA, Scardino PT, Huland H, Lilja H.
Int J Cancer 2007;120:1499-1504.
Download
URL : Abstract
|
|
Molecular markers for prostate cancer.
Reynolds MA, Kastury K, Groskopf J, Schalken JA, Rittenhouse H.
Cancer Lett 2007;249:5-13.
Download
URL : Abstract
|
|
Overdiagnosis and overtreatment of early detected prostate cancer.
Bangma CH, Roemeling S, Schröder FH
World J Urol 2007;25:3-9.
Download
URL : Full text (PDF)
|
|
A highly conserved protein secreted by the prostate cancer cell line PC-3 is expressed in benign and malignant prostate tissue.
Valtonen-André C, Bjartell A, Johansson R, Lilja H, Härkönen P, Lundwall Å.
Biol Chem. 2007; 388:289-295.
Download
URL : Abstract
|
|
Depletion of high-abundance proteins from serum by immunoaffinity chromatography: a MALDI-FT-MS study.
Dekker LJ, Bosman J, Burgers PC, van Rijswijk A, Freije R, Luider T, Bischoff R.
J Chromatogr B Analyt Technol Biomed Life Sci, 2007;847:65-9.
Download
URL : Abstract
|
|
Overall and disease-specific survival of patients with screen-detected prostate cancer in the European randomized study of screening for prostate cancer, section Rotterdam.
de Vries SH, Postma R, Raaijmakers R, Roemeling S, Otto S, de Koning HJ, Schroder FH.
Eur Urol. 2007;51:366-74; discussion 374
Download
URL : Abstract
|
|
Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer.
Steuber T, Vickers AJ, Serio AM, Vaisanen V, Haese A, Pettersson K, Eastham JA, Scardino PT, Huland H, Lilja H.
Clin Chem. 2007;53:233-40.
Download
URL : Abstract
|
|
The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance.
van Gils MP, Hessels D, van Hooij O, Jannink SA, Peelen WP, Hanssen SL, Witjes JA, Cornel EB, Karthaus HF, Smits GA, Dijkman GA, Mulders PF, Schalken JA.
Clin Cancer Res. 2007;13:939-43.
Download
URL : Abstract
|
|
[Validatie van de PCA3-urinetest in een Nederlandse mulitcenter studie.]
van Gils MPMQ, Hessels D, van Hooij O, Jannink SA, Peelen WP, Hanssen SLJ, Witjes JA, Cornel EB, Karthaus HFM, Smits GAHJ, Dijkman GA, Mulders PFA, Schalken JA.
Nederlands Tijdschrift voor Urologie. 2007;2:48-53.
Download
|
|
An interim report on the P-Mark project.
Schenk E, Bangma C.
Eur Urol Today 2007;19:13.
Download
|
|
Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.
Lilja H, Ulmert D, Björk T, Becker C, Serio AM, Nilsson JÅ, Abrahamsson PA, Vickers AJ, Berglund G.
J Clin Oncol 2007; 25:431-436
Download
URL : Abstract
|
|
Novel homogenous time-resolved fluorometric RT-PCR assays for quantification of PSA and hK2 mRNAs in blood.
Rissanen M, Helo P, Vaananen RM, Wahlroos V, Lilja H, Nurmi M, Pettersson K, Nurmi J.
Clin Biochem. 2007;40:111-8.
Download
URL : Abstract
|
|
Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram.
Steyerberg EW, Roobol MJ, Kattan MW, van der Kwast TH, de Koning HJ, Schroder FH.
J Urol. 2007;177:107-12; discussion 112.
Download
URL : Abstract
|
|
PSA Doubling Time predicts the outcome after active surveillance in screening-detected prostate cancer: Results from the European Randomized Study of Screening for Prostate Cancer, Sweden section
Khatami A, Aus G, Damber J-E, Lilja H, Lodding P, Hugosson J.
Int J Cancer 2007;120:170-174.
Download
URL : Abstract
|
|
Metastatic disease of screen-detected prostate cancer: characteristics at diagnosis.
Roemeling S, Kranse R, Vias AN, Gosselaar C, Van der Kwast TH, Schröder FH.
Cancer 2006 Dec 15;107(2):2779-85.
Download
|
|
Site-specific glycan analysis of human chorionic gonadotropin beta-subunit from malignancies and pregnancy by liquid chromatography - electrospray mass spectrometry.
Valmu L, Alfthan H, Hotakainen K, Birken S, Stenman UH.
Glycobiology 2006;16:1207-18.
Download
URL : Abstract
|
|
Intact Free Prostate-Specific Antigen and Free and Total Human Glandular Kallikrein 2. Elimination of Assay Interference by Enzymatic Digestion of Antibodies to Fab2 Fragments.
Väisänen V, Peltola MT, Lilja H, Nurmi M, Pettersson K.
Anal Chem 2006;78:7809-15.
Download
URL : Abstract
|
|
A database application for pre-processing, storage and comparison of mass spectra derived from patients and controls.
Titulaer MK, Siccama I, Dekker LJ, van Rijswijk AL, Heeren RM, Sillevis Smitt PA, Luider TM.
BMC Bioinformatics 2006;7:403.
Download
URL : Full text (PDF)
|
|
[The search for better markers for prostate cancer than prostate-specific antigen].
Schenk-Braat EAM, Bangma CH.
Ned Tijdschr Geneeskd 2006;150:1286-1290.
Download
URL : Abstract
|
|
[Bepaling van het individuele risico op prostaatkanker en indolente tumoren].
Bangma C, Roobol M, Schröder F.
Nederlands Tijdschrift voor Urologie. 2006
Download
|
|
Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance.
Roemeling S, Roobol MJ, Postma R, Gosselaar C, van der Kwast TH, Bangma CH, Schroder FH.
Eur Urol 2006;50:475-82.
Download
URL : Abstract
|
|
Biochemical progression rates in the screen arm compared to the control arm of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Roemeling S, Roobol MJ, Gosselaar C, Schroder FH.
Prostate 2006;66:1076-81.
Download
URL : Abstract
|
|
Free and total human glandular kallikrein 2 in patients with prostate cancer.
Väisänen V, Pettersson K, Alanen K, Viitanen T, Nurmi M.
Urology 2006;68:219-25.
Download
URL : Abstract
|
|
A comparison of first and repeat (four years later) prostate cancer screening in a randomized cohort of a symptomatic men aged 55-75 years using a biopsy indication of 3.0 ng/ml (results of ERSPC, Rotterdam).
Roobol MJ, Schroder FH, Kranse R; ERSPC, Rotterdam.
Prostate 2006;66:604-12.
Download
URL : Abstract
|
|
Immunohistochemical detection of cysteine-rich secretory protein 3 in tissue and in serum from men with cancer or benign enlargement of the prostate gland.
Bjartell A, Johansson R, Bjork T, Gadaleanu V, Lundwall A, Lilja H, Kjeldsen L, Udby L.
Prostate 2006;66:591-603.
Download
URL : Abstract
|
|
Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum.
Piironen T, Haese A, Huland H, Steuber T, Christensen IJ, Brunner N, Dano K, Hoyer-Hansen G, Lilja H.
Clin Chem 2006;52:838-44.
Download
URL : Full text (PDF)
|
|
Prostate cancer: risks and benefits of screening.
Roemeling S, Schroder FH.
Nat Clin Pract Urol 2006;3:4-5.
Download
URL : Abstract
|
|
Does PSA velocity predict prostate cancer in pre-screened populations?
Schröder FH, Roobol MJ, van der Kwast TH, Kranse R, Bangma CH.
Eur Urol 2006;49:460-5.
Download
URL : Abstract
|
|
Risk assessment for biochemical recurrence prior to radical prostatectomy: Significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.
Steuber T, Vickers AJ, Haese A, Becker C, Pettersson K, Chun FK, Kattan MW, Eastham JA, Scardino PT, Huland H, Lilja H.
Int J Cancer 2006 ;118:1234-40.
Download
URL : Full text (PDF)
|
|
High-speed biomarker identification utilizing porous silicon nanovial arrays and MALDI-TOF mass spectrometry.
Finnskog D, Jaras K, Ressine A, Malm J, Marko-Varga G, Lilja H, Laurell T.
Electrophoresis 2006;27:1093-103.
Download
URL : Abstract
|
|
Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C.
Ulmert D, Becker C, Nilsson JA, Piironen T, Bjork T, Hugosson J, Berglund G, Lilja H.
Clin Chem 2006;52:235-9.
Download
URL : Full text (PDF)
|
|
Interview with Jack Schalken. PCA3 and its use as a diagnostic test in prostate cancer.
Schalken J.
Eur Urol 2006;50:153-4.
Download
|
|
Validation of molecular targets in prostate cancer.
Schalken, JA.
BJU Int. 2005;96 Suppl 2:23-9.
Download
URL : Abstract
|
|
Innovations in Serum and Urine Markers in Prostate Cancer Current European Research in the P-Mark Project.
van Gils MP, Stenman UH, Schalken JA, Schroder FH, Luider TM, Lilja H, Bjartell A, Hamdy FC, Pettersson KS, Bischoff R, Takalo H, Nilsson O, Mulders PF, Bangma CH.
Eur Urol 2005;48:1031-1041.
Download
URL : Abstract
|
|
Assessment of intra-individual variation in prostate-specific antigen levels in a biennial randomized prostate cancer screening program in Sweden.
Bruun L, Becker C, Hugosson J, Lilja H, Christensson A.
Prostate 2005;65:216-21.
Download
URL : Full text (PDF)
|
|
A new method to analyze matrix-assisted laser desorption/ionization time-of-flight peptide profiling mass spectra.
Dekker LJ, Dalebout JC, Siccama I, Jenster G, Sillevis Smitt PA, Luider TM.
Rapid Commun Mass Spectrom 2005;19:865-70.
Download
URL : Abstract
|
|
Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study.
Aus G, Damber JE, Khatami A, Lilja H, Stranne J, Hugosson J.
Arch Intern Med. 2005;165:1857-61.
Download
URL : Full text (PDF)
|
|
The evolution of a genetic locus encoding small serine proteinase inhibitors.
Clauss A, Lilja H, Lundwall A.
Biochem Biophys Res Commun 2005;333:383-9.
Download
URL : Full text (PDF)
|
|
beta-Microseminoprotein binds CRISP-3 in human seminal plasma.
Udby L, Lundwall A, Johnsen AH, Fernlund P, Valtonen-Andre C, Blom AM, Lilja H, Borregaard N, Kjeldsen L, Bjartell A.
Biochem Biophys Res Commun 2005;333:555-61.
Download
URL : Full text (PDF)
|
|
Molecular prostate cancer pathology: current issues and achievements.
Schalken JA, Bergh A, Bono A, Foster C, Gospadarowicz M, Isaacs WB, Rubin M, Schröder F, Tribukait B, Tsukamotot T, Wiklund P.
Scand J Urol Nephrol Suppl 2005;216:82-93.
Download
URL : Abstract
|
|
Bioinformatics used in the EU P-Mark project for biomarker discovery.
Titulaer M, Dekker L, van Rijswijk A, Bangma C, Luider T.
European Urology Today 2005;17(4):9-10.
Download
|
|
From urine and serum to peptide/protein identification.
Bjartell A.
European Urology Today 2005;17(3):3+11.
Download
|
|
[Zoektocht naar betere merkstoffen prostaatkanker.]
Bangma CH.
Tijdschr. v. Huisartsgeneeskunde 2005;22:16-17.
Download
|
|
The establishment of prostate cancer biorepositories: “garbage in, garbage out”.
Schalken JA.
European Urology Today 2005;17(1):11.
Download
|
|
P-Mark comes to life.
Bangma CH, Schenk E.
European Urology Today 2004;16(4):3.
Download
|
|
Essential proteomics for urologists.
Rehman I, Azzouzi A-R, Catto JWF, Hamdy FC.
European Urology Today 2004;16(4):14.
Download
|
|
European Community projects in urology.
EC-activity members (ECAM: Bangma CH, Bjartell A, Culig Z, Hamdy F, Maitland N, Schalken J).
European Urology Today 2004;16(2):3.
Download
|
|
|
|
